Now reading Entry 004 / 102 Last revised Jan 28, 2026 200 sources 1 comparisons Methodology →
A specimen of the Immune drawer Drawer F · Immune

Alpha-Defensins

Research Only

A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.

HNP-1 · HNP-2 · HNP-3 · HNP-4 · HD-5 · HD-6 · Human Neutrophil Peptides · Human Defensins

Research evidence
Moderate

40 human studies

Preclinical
80%
Human research
20%

Based on 200 cited sources

Numeric assessment unreviewed

A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.

This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.

Scoring context and limitations
~
Evidence Level
moderate
Not FDA-approved as therapeutics.
Research Only
Identity
SCALE · 1:1 N-TERMINUS C-TERMINUS 30 AA · 3,442 Da
Also Known As
HNP-1 • HNP-2 • HNP-3 • HNP-4 • HD-5 • HD-6 • Human Neutrophil Peptides • Human Defensins
Class
Cationic antimicrobial peptide
Length
30 amino acids
Mol. weight
3,442 Da
Sequence
ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Molecular Structure
A
C
Y
C
R
I
P
A
C
I
A
G
E
R
R
Y
G
T
C
I
Y
Q
G
R
L
W
A
F
C
C
Hydrophobic
Polar
Positive
Negative

Alpha-defensins are endogenous antimicrobial peptides with well-characterized mechanisms supported by extensive structural and functional studies from multiple independent research groups worldwide.

How It Works (Simplified)

Alpha-defensins function as key effectors of innate immunity through several pathways:

Membrane Disruption

Cationic peptides bind to anionic microbial membranes, insert into lipid bilayer, and form pores causing ion leakage and cell death.

Immune Signaling

Recruit and activate immune cells including T cells and dendritic cells, bridging innate and adaptive immunity responses.

Nanonet Formation

HD-6 self-assembles into fiber structures that physically trap bacteria, representing a unique non-lytic defense mechanism.

Antiviral Activity

Directly inactivate viral particles, block entry receptors, and interfere with fusion to inhibit viral replication.

Key Research: Selsted ME et al. (UCLA, 1985) first characterized HNP structure and antimicrobial mechanism. PMID:4056036

Important Limitations

  • Salt sensitivity reduces antimicrobial activity in physiological conditions (150 mM NaCl)
  • In vitro MIC values may overestimate in vivo efficacy
  • No alpha-defensin therapeutics currently approved despite decades of research
  • High synthesis cost due to complex disulfide bonding (3 intramolecular bonds)
  • Concentration-dependent cytotoxicity may limit therapeutic window
i. Antimicrobial Membrane Disruption · Primary Mechanism
Alpha-defensin (cationic)Electrostatic binding to anionic membraneInsertion into lipid bilayerPore formationIon leakageCell death
ii. HD-6 Nanonet Formation · Unique to HD-6
HD-6 monomersSelf-assemblyNanonet fiber formationPhysical bacterial trapping
Mechanism Membrane disruption via electrostatic interaction with anionic microbial membranes
Established 50 direct studies
Benefit shown to provide broad-spectrum antimicrobial defense
Evidence Level
Moderate
20 Human
40 Animal
100 In Vitro
Mechanism Chemotactic signaling and dendritic cell activation bridging innate-adaptive immunity
Supported 15 direct studies
Benefit appears to enhance immune response coordination
Evidence Level
Moderate
10 Human
20 Animal
30 In Vitro
Mechanism HD-6 self-assembly into nanonets for physical bacterial entrapment
Supported 5 direct studies
Benefit shown to trap and neutralize intestinal pathogens
Evidence Level
Moderate
3 Human
8 Animal
10 In Vitro
Mechanism Direct virion inactivation and viral entry receptor blockade
Supported 10 direct studies
Benefit may inhibit viral infections
Evidence Level
Low
5 Human
10 Animal
20 In Vitro
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low
Phase 01 1
Immediate

Alpha-defensins are released within seconds to minutes during neutrophil degranulation or Paneth cell secretion. Antimicrobial activity is immediate upon contact with target pathogens. Membrane disruption occurs within minutes of peptide-pathogen interaction.

PMID:4056036
Phase 02 2
Hours

Chemotactic signaling begins, recruiting additional immune cells to sites of infection. Immunomodulatory effects on dendritic cells and T cells initiate within hours of defensin release.

PMID:8621683
Phase 03 3
Days

Sustained antimicrobial defense through continued neutrophil recruitment and Paneth cell secretion. HD-6 nanonet formation provides ongoing physical barrier against intestinal pathogens.

PMID:22722251
Phase 04 4
Chronic

Long-term defensin deficiency (as seen in Crohn's disease) associated with dysbiosis and increased susceptibility to intestinal infections. Therapeutic supplementation timelines are not established due to lack of clinical trials.

PMID:17709525

Research-based observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Synergistic
Compatible
Caution
Avoid

LL-37

Synergistic
Synergistic

Both are cationic antimicrobial peptides with complementary mechanisms. Alpha-defensins and LL-37 may work synergistically to provide broad-spectrum antimicrobial coverage. No direct clinical studies on combination.

Beta-Defensins

Compatible
Compatible

Different tissue distribution (alpha-defensins in neutrophils/Paneth cells vs beta-defensins in epithelial cells). Complementary innate immunity coverage with no known contraindications.

Thymosin-Alpha-1

Compatible
Compatible

Alpha-defensins provide direct antimicrobial action while Thymosin Alpha-1 modulates adaptive immunity. Theoretical complementary benefits for immune function.

BPC-157

Compatible
Compatible

Non-overlapping mechanisms. Alpha-defensins focus on antimicrobial defense while BPC-157 targets tissue repair. No interaction studies available.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

200 Sources 40 Human 160 Preclinical

Key Studies Cited

In Vitro Selsted ME et al. 1985
PMID:4056036
Review Ganz T et al. 2003
PMID:12949495
In Vitro Chertov O et al. 1996
PMID:8621683
Review Lehrer RI et al. 1993
PMID:8476558
Animal Chu H et al. 2012
PMID:22722251
Human Wehkamp J et al. 2007
PMID:17709525
In Vitro Chang TL et al. 2003
PMID:12767998
Review Klotman ME et al. 2006
PMID:16724099

Use the source links in the research discussion above to inspect the referenced records.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare Alpha-Defensins

Alpha-Defensins vs LL-37
View comparison

Related Peptides

Immune

KPV

Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1

Lys-Pro-Val is the C-terminal tripeptide motif of alpha-MSH. KPV reduced inflammatory readouts in cell and mouse colitis models, including a PepT1 uptake study. Human drug exposure, pharmacokinetics, safety and clinical benefit remain unestablished.

See dossier
Immune

Kristagen

EDG · Glu-Asp-Gly · Immune tripeptide

A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.

See dossier
Immune

Lactoferricin

LFcinB · Lactoferricin B · LfcinB +1

An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.

See dossier
Immune

Murepavadin

POL7080 · RG7929

A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.

See dossier
Immune

Thymalin

Thymulin · Thymic Factor · Timalin +1

A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.

See dossier
Immune

Thymogen

Glu-Trp · EW dipeptide · Timogen +2

A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.

See dossier

Compared With

1 comparison

Conditions Studied

3 entries

Related Content

Peptide

LL-37

Immune · low evidence

Comparison

LL-37 vs Alpha-Defensins

View side-by-side analysis